Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
59.67(c) 58.74(c) 57.76(c) 57.92(c) 58.45(c) Last
7 484 139 10 008 246 11 931 155 8 838 608 11 102 025 Volume
-0.77% -1.56% -1.67% +0.28% +0.92% Change
More quotes
Financials (USD)
Sales 2020 42 040 M - -
Net income 2020 1 479 M - -
Net Debt 2020 32 201 M - -
P/E ratio 2020 209x
Yield 2020 3,06%
Sales 2021 45 733 M - -
Net income 2021 8 202 M - -
Net Debt 2021 26 431 M - -
P/E ratio 2021 14,3x
Yield 2021 3,27%
Capitalization 132 B 132 B -
EV / Sales 2020 3,90x
EV / Sales 2021 3,46x
Nbr of Employees 30 000
Free-Float 77,0%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
10/30Presentation
More about the company
Notations Surperformance© of Bristol-Myers Squibb Company
Trading Rating : Investor Rating :
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
10/28Ono and Takeda Submit Supplemental Application for Opdivo and CABOMETYX Combi..
AQ
10/26BRISTOL MYERS SQUIBB : Decreases in Americans' Primary Care Visits May Lead to L..
BU
10/23Sensyne to Collaborate with Bristol Myers Squibb on Blood-Disease Research
DJ
10/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
AQ
10/19BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Opdivo as Sec..
AQ
10/19BRISTOL MYERS SQUIBB : Exelixis Get Priority Review for Kidney-Cancer Treatment
DJ
10/19BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
BU
10/16BRISTOL MYERS SQUIBB : Gets Positive CHMP Opinion for Opdivo in Esophageal Cance..
DJ
10/16BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Opdivo (nivol..
BU
10/16NIH to Study Three Drugs in Treatment of Covid-19 Patients
DJ
10/16Biopharmaceutical Industry Drives Global Dual Chamber Prefilled Syringes Mark..
AQ
10/12BRISTOL MYERS SQUIBB : Event Slides
PU
10/10BRISTOL MYERS SQUIBB : Presents Positive Late-Breaking Data from Phase 3 True No..
BU
10/08BRISTOL MYERS SQUIBB : Opdivo Plus Chemotherapy Shows Statistically Significant ..
AQ
10/07BRISTOL MYERS SQUIBB : Health Canada Approves ZEPOSIAģ, an Oral Treatment for Re..
AQ
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
10/08Evotec und Bristol Myers Squibb bauen Alzheimer-Kooperation aus
10/08Evotec und Bristol Myers Squibb bauen Alzheimer-Kooperation aus
10/07Les valeurs à suivre mercredi 7 octobre 2020 à Wall Street -
10/07BRISTOL-MYERS SQUIBB : résultats encourageants contre le cancer du poumon
10/07BRISTOL MYERS : données positives dans le cancer du poumon
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 73,56 $
Last Close Price 58,45 $
Spread / Highest target 50,6%
Spread / Average Target 25,9%
Spread / Lowest Target 9,50%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-8.94%130 548
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493